DBV Technologies (NASDAQ:DBVT) Sees Unusually-High Trading Volume Following Analyst Upgrade

Shares of DBV Technologies S.A. (NASDAQ:DBVT) saw strong trading volume on Thursday after Citizens Jmp raised their price target on the stock from $21.00 to $45.00. Citizens Jmp currently has a market outperform rating on the stock. 269,934 shares traded hands during trading, an increase of 23% from the previous session’s volume of 219,139 shares.The stock last traded at $20.9540 and had previously closed at $22.55.

A number of other analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price (up previously from $20.00) on shares of DBV Technologies in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a report on Monday, December 8th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Wednesday. Zacks Research upgraded DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Finally, Cantor Fitzgerald upgraded DBV Technologies to a “strong-buy” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.38.

Institutional Trading of DBV Technologies

A number of institutional investors have recently added to or reduced their stakes in DBVT. Vivo Capital LLC bought a new stake in DBV Technologies during the 2nd quarter valued at $9,659,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the second quarter worth $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies during the 2nd quarter worth $9,649,000. Octagon Capital Advisors LP acquired a new stake in DBV Technologies during the 2nd quarter worth about $9,315,000. Finally, Millennium Management LLC raised its position in shares of DBV Technologies by 26.1% in the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after acquiring an additional 69,849 shares during the period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Price Performance

The stock has a market capitalization of $839.67 million, a PE ratio of -3.99 and a beta of -1.10. The company’s 50 day moving average price is $15.11 and its two-hundred day moving average price is $11.66.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.